Impact of Immune-Modulatory Drugs on Regulatory T Cell

Transplantation

Volumn 100, Issue 11, 2016, Pages 2288-2300

  Furukawa, Akiko ^a   Wisel, Steven A ^a   Tang, Qizhi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCITRIOL; CD28 ANTIGEN; CD86 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DEXAMETHASONE; EFALIZUMAB; EVEROLIMUS; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY CD28; MYCOPHENOLATE MOFETIL; RAPAMYCIN; RETINOIC ACID; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY; TOFACITINIB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; CALCINEURIN INHIBITOR; CD52 ANTIGEN; GLYCOPROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 RECEPTOR; LEUKOCYTE ANTIGEN; TARGET OF RAPAMYCIN KINASE; TUMOR ANTIGEN; VITAMIN D;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HEART TRANSPLANTATION; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCYTE FUNCTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CALCINEURIN INHIBITORS; GLYCOPROTEINS; HOMEOSTASIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; RECEPTORS, INTERLEUKIN-6; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES; VITAMIN D;

EID: 84982838771     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001379     Document Type: Review

References (249)

1. Tang Q, Bluestone JA. The Foxp3+ regulatory Tcell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239-244.
2. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med. 2013;3.
3. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38:414-423.
4. Liu ZM, Wang KP, Ma J, et al. The role of all-trans retinoic acid in the biology of Foxp3(+) regulatory T cells. Cell Mol Immunol. 2015;12:553-557.
5. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010;184: 3433-3441.
6. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory Tcells among regulatory Tcell subsets in vivo. J Exp Med. 2012;209:1713-1722, S1-19.
7. Haribhai D, Williams JB, Jia S, et al. A requisite role for induced regulatory Tcells in tolerance based on expanding antigen receptor diversity. Immunity. 2011;35:109-122.
8. Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science. 2015;350: 334-339.
9. Himmel ME, MacDonald KG, Garcia RV, et al. Helios + and Helios-cells coexist within the natural FOXP3+ Tregulatory cell subset in humans. J Immunol. 2013;190:2001-2008.
10. Lee HM, Bautista JL, Hsieh CS. Thymic and peripheral differentiation of regulatory Tcells. Adv Immunol. 2011;112:25-71.
11. Yu A, Snowhite I, Vendrame F, et al. Selective IL-2 responsiveness of regulatory Tcells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64: 2172-2183.
12. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory Tcells: howdothey sup-press immune responses? Int Immunol. 2009;21:1105-1111.
13. Yuan X, Dee MJ, Altman NH, et al. IL-2Rβ-dependent signaling and CD103 functionally cooperate to maintain tolerance in the gut mucosa. J Immunol. 2015;194:1334-1346.
14. Cobbold SP, Waldmann H. Regulatory cells and transplantation tolerance. Cold Spring Harb Perspect Med. 2013;3.
15. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363:1451-1462.
16. Lowenberg M, Stahn C, Hommes DW, et al. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids. 2008;73:1025-1029.
17. Gardner D, Jeffery LE, Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant. 2014;14:1985-1991.
18. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-2729.
19. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014;98:312-319.
20. Gaber AO, Monaco AP, Russell JA, et al. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs. 2010;70:691-732.
21. Grafals M, Smith B, Murakami N, et al. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS One. 2014;9:e104408.
22. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood. 1998;91:2360-2368.
23. Préville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation. 2001;71:460-468.
24. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation. 1998; 65:1481-1489.
25. Mourad G, Morelon E, Noel C, et al. The role of Thymoglobulin induction in kidney transplantation: an update. Clin Transplant. 2012;26:E450-E464.
26. Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003;75:657-662.
27. Chappell D, Beiras-Fernandez A, Hammer C, et al. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation. 2006;81: 552-558.
28. Shimony O, Nagler A, Gellman YN, et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J Clin Immunol. 2012;32:173-188.
29. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4 + CD25 + Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006;17:2844-2853.
30. Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4 + CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111:3675-3683.
31. Broady R, Yu J, Levings MK. ATG-induced expression of FOXP3 in human CD4(+) T cells in vitro is associated with T-cell activation and not the induction of FOXP3(+) T regulatory cells. Blood. 2009;114: 5003-5006.
32. Tang Q, Leung J, Melli K, et al. Altered balance between effector Tcells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012;25:1257-1267.
33. D'Addio F, Yuan X, Habicht A, et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Trans-plantation. 2010;90:260-269.
34. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant. 2010;10:2132-2141.
35. Na IK, Wittenbecher F, Dziubianau M, et al. Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ Tcells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica. 2013;98:23-30.
36. Xia CQ, Chernatynskaya AV, Wasserfall CH, et al. Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice. BMC Immunol. 2012;13:70.
37. Pascual J, Marcén R, Ortuño J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant. 2001;16: 1756-1760.
38. Du J, Yang H, Zhang D, et al. Structural basis for the blockage ofIL-2 signaling by therapeutic antibody basiliximab. J Immunol. 2010;184: 1361-1368.
39. Yang H, Wang J, Du J, et al. Structural basis of immunosuppression by the therapeutic antibody daclizumab. Cell Res. 2010;20:1361-1371.
40. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394-404.
41. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated Tcell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17:604-609.
42. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells-A proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145-149.
43. Lin YC, Winokur P, Blake A, et al. Daclizumab reverses intrathecal im-mune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol. 2015;2:445-455.
44. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med. 2012;4:145ra106.
45. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antag-onists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77:166-176.
46. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001;72:839-845.
47. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and in-terleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008;8:2086-2096.
48. Bouvy AP, Klepper M, Kho MM, et al. The impact of induction therapy on the homeostasis and functionofregulatoryTcellsinkidney transplant patients. Nephrol Dial Transplant. 2014;29:1587-1597.
49. Zhao T, Yang C, Xue Y, et al. Impact of basiliximab on the proportion of regulatory Tcells and their subsets early after renal transplantation: a preliminary report. Transplant Proc. 2012;44:175-178.
50. Krystufkova E, Sekerkova A, Striz I, et al. Regulatory T cells in kidney transplant recipients: the effectofinduction immunosuppression therapy. Nephrol Dial Transplant. 2012;27:2576-2582.
51. Wang Z, Shi BY, Qian YY, et al. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory Tcells in kidney transplantation. Clin Exp Immunol. 2009;155:496-503.
52. Vondran FW, Timrott K, Tross J, et al. Impactof Basiliximab onregulatory T-cells early after kidney transplantation: down-regulation of CD25 by re-ceptor modulation. Transpl Int. 2010;23:514-523.
53. Greenland JR, Wong CM, Ahuja R, et al. Donor-reactive regulatory T-cell frequency increases during acute cellular rejection of lung allografts. Transplantation. 2016.
54. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701-1711.
55. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated Tcells. J Exp Med. 2006;203:1693-1700.
56. Martin JF, Perry JS, Jakhete NR, et al. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol. 2010;185:1311-1320.
57. Jiang W, Chai NR, Maric D, et al. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol. 2011;187:781-790.
58. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103:5941-5946.
59. Garrod KR, Liu FC, Forrest LE, et al. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. J Immunol. 2010;184:2329-2336.
60. Hu Y, Turner MJ, Shields J, et al. Investigation ofthe mechanism ofaction of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260-270.
61. Coles AJ. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:29-33.
62. Morgan RD, O'Callaghan JM, Knight SR, et al. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2012;93:1179-1188.
63. Mavromatis B, Cheson BD. Monoclonal antibody therapy ofchronic lym-phocytic leukemia. J Clin Oncol. 2003;21:1874-1881.
64. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs. 2003;17:147-154.
65. Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine modelofadult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63:6453-6457.
66. Lowenstein H, Shah A, Chant A, et al. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 Tcells in peripheral blood. Transpl Int. 2006;19:927-936.
67. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia. 2006;20:272-279.
68. Macedo C, Walters JT, Orkis EA, et al. Long-term effects ofalemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation. 2012;93:813-821.
69. Trzonkowski P, Zilvetti M, Friend P, et al. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation. 2006;82:1342-1351.
70. Dons EM, Raimondi G, Zhang H, et al. Ex vivo-expanded cynomolgus macaque regulatory Tcells are resistant to alemtuzumab-mediated cyto-toxicity. Am J Transplant. 2013;13:2169-2178.
71. Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory Tcells in vitro. Immunology. 2014;141:123-131.
72. De Serres SA, Mfarrej BG, Magee CN, et al. Immune profile of pediat-ric renal transplant recipients following alemtuzumab induction. J Am Soc Nephrol. 2012;23:174-182.
73. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant. 2008;8:793-802.
74. Toh BH, Kyaw T, Tipping P, et al. Immune regulationby CD52-expressing CD4 Tcells. Cell Mol Immunol. 2013;10:379-382.
75. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol. 2006; 120:247-259.
76. Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191:5867-5874.
77. Clark M, Cooke A. Regulation unmasked by activation. Nat Immunol. 2013;14:696-697.
78. Bandala-Sanchez E, Zhang Y, Reinwald S, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol. 2013;14:741-748.
79. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255-266.
80. Razi N, Varki A. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology. 1999;9:1225-1234.
81. Kivi E, Elima K, Aalto K, et al. Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood. 2009;114: 5385-5392.
82. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 annual data report: kidney. Am J Transplant. 2015;15(Suppl 2):1-34.
83. Moes AD, Hesselink DA, Zietse R, et al. Calcineurin inhibitors and hyper-tension: a role for pharmacogenetics? Pharmacogenomics. 2014;15: 1243-1251.
84. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspec-tive toward individually optimized drug doses of cyclosporine A. Trans-plantation. 2004;77:339-344.
85. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15: 283-294.
86. Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev. 2011;241:63-76.
87. Miroux C, Morales O, Ghazal K, et al.Invitro effects ofcyclosporineAand tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94:123-131.
88. Tone Y, Furuuchi K, Kojima Y, et al. Smad3 and NFAT cooperate to in-duce Foxp3 expression through its enhancer. Nat Immunol. 2008;9: 194-202.
89. Huehn J, Beyer M. Epigenetic and transcriptional control of Foxp3+ regulatory Tcells. Semin Immunol. 2015;27:10-18.
90. Li X, Liang Y, LeBlanc M, et al. Function of a Foxp3 cis-element in protecting regulatory T cell identity. Cell. 2014;158:734-748.
91. Akimova T, Kamath BM, Goebel JW, et al. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant. 2012;12:3449-3461.
92. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108:390-399.
93. Gallon L, Traitanon O, Yu Y, et al. Differential effects of calcineurin and mammalian target of rapamycin inhibitors on alloreactive Th1, Th17, and regulatory T cells. Transplantation. 2015;99:1774-1784.
94. Li Q, Shakya A, Guo X, et al. Constitutive nuclear localization of NFAT in Foxp3+ regulatory Tcells independent of calcineurin activity. J Immunol. 2012;188:4268-4277.
95. Brandt C, Pavlovic V, Radbruch A, et al. Low-dose cyclosporine A ther-apy increases the regulatory Tcell population in patients with atopic dermatitis. Allergy. 2009;64:1588-1596.
96. Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, et al. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level. Transpl Immunol. 2009;21:43-49.
97. Vaeth M, Schliesser U, Muller G, et al. Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc Natl Acad Sci USA. 2012;109:16258-16263.
98. Satake A, Schmidt AM, Archambault A, et al. Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory Tcells while inhibiting conventional Tcells. J Autoimmun. 2013; 44:13-20.
99. Yamada Y, Nadazdin O, Boskovic S, et al. Repeated injections of IL-2 break renal allograft tolerance induced via mixed hematopoietic chime-rism in monkeys. Am J Transplant. 2015;15:3055-3066.
100. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory Tcells in graft-versus-host disease. N Engl J Med. 2011;365:2055-2066.
101. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory Tcell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra143.
102. Kennedy-Nasser AA, Ku S, Castillo-Caro P, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014; 20:2215-2225.
103. Siepert A, Ahrlich S, Vogt K, et al. Permanent CNI treatment for preven-tion of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. Am J Transplant. 2012;12:2384-2394.
104. Levitsky J, Mathew JM, Abecassis M, et al. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology. 2013;57:239-248.
105. Kitchin JE, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol. 1997;37(3 Pt 1):445-449.
106. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005; 80(2 Suppl):S181-S190.
107. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993;268:27286-27290.
108. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000; 165:2374-2381.
109. Lim DG, Joe IY, Park YH, et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl Immunol. 2007;18:94-100.
110. Abadja F, Atemkeng S, Alamartine E, et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation. 2011;92:396-403.
111. Degauque N, Mariat C, Kenny J, et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest. 2008;118:735-741.
112. Abadja F, Videcoq C, Alamartine E, et al. Differential effect of cyclosporine and mycophenolic acid on the human regulatory Tcells and TH-17 cells balance. Transplant Proc. 2009;41:3367-3370.
113. Lim DG, Koo SK, Park YH, et al. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4 + CD25 + Foxp3+ regulatory T cells in allotransplantation. Transplantation. 2010;89:928-936.
114. Demirkiran A, Sewgobind VD, van der Weijde J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppres-sion changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation. 2009;87:1062-1068.
115. Fourtounas C, Dousdampanis P, Sakellaraki P, et al. Different immuno-suppressive combinations on T-cell regulation in renal transplant recipients. Am J Nephrol. 2010;32:1-9.
116. Vandevyver S, Dejager L, Tuckermann J, et al. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013; 154:993-1007.
117. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003;24:488-522.
118. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory re-sponses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev. 1999;20:435-459.
119. Lowenberg M, Verhaar AP, van den Brink GR, et al. Glucocorticoid sig-naling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med. 2007;13:158-163.
120. Muller N, Fischer HJ, Tischner D, et al. Glucocorticoids induce effector T cell depolarization via ERM proteins, thereby impeding migration and APC conjugation. J Immunol. 2013;190:4360-4370.
121. Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8:473-479.
122. Mahata B, Zhang X, Kolodziejczyk AA, et al. Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis. Cell Rep. 2014;7:1130-1142.
123. Tuckermann JP, Kleiman A, McPherson KG, et al. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci. 2005;42:71-104.
124. Chen X, Oppenheim JJ, Winkler-Pickett RT, et al. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol. 2006;36:2139-2149.
125. Suarez A, Lopez P, Gomez J, et al. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis. 2006;65:1512-1517.
126. Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregu-late FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114:1425-1433.
127. Seissler N, Schmitt E, Hug F, et al. Methylprednisolone treatment in-creases the proportion of the highly suppressive HLA-DR(+)-Tregs in transplanted patients. Transpl Immunol. 2012;27:157-161.
128. Bereshchenko O, Coppo M, Bruscoli S, et al. GILZ promotes production of peripherally induced Tregs and mediates the crosstalk between gluco-corticoids and TGF-β signaling. Cell Rep. 2014;7:464-475.
129. Libert C, Dejager L. How steroids steer T cells. Cell Rep. 2014;7:938-939.
130. Garber K. Targeting mTOR: something old, something new. J Natl Cancer Inst. 2009;101:288-290.
131. Singh K, Sun S, Vézina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. IV. Mechanism of action. J Antibiot (Tokyo). 1979;32:630-645.
132. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22: 159-168.
133. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457-468.
134. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 con-trols the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122-1128.
135. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011;12:295-303.
136. Pollizzi KN, Patel CH, Sun IH, et al. mTORC1 and mTORC2 selectively regulate CD8(+) Tcell differentiation. J Clin Invest. 2015;125:2090-2108.
137. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460:108-112.
138. Spence A, Klementowicz JE, Bluestone JA, et al. Targeting Treg signaling for the treatment ofautoimmune diseases. Curr Opin Immunol. 2015;37: 11-20.
139. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory Tcell lineage commitment. Immunity. 2009; 30:832-844.
140. Huynh A, DuPage M, Priyadharshini B, et al. Control of PI(3) kinase in Tregs maintains homeostasis and lineage stability. Nat Immunol. 2015; 16:188-196.
141. Shrestha S, Yang K, Guy C, et al. Tregs require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol. 2015; 16:178-187.
142. Basu S, Golovina T, Mikheeva T, et al. Cutting edge: Foxp3-mediated in-duction of pim 2 allows human Tregulatory cells to preferentially expand in rapamycin. J Immunol. 2008;180:5794-5798.
143. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008; 111:453-462.
144. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4 + CD25 + FoxP3+ regulatory Tcells. Blood. 2005;105:4743-4748.
145. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory Tcells. Am J Transplant. 2007;7:1722-1732.
146. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory Tcells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3:83ra41.
147. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation. 2007;84:956-964.
148. Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the ran-domized ZEUS study. Am J Transplant. 2015;15:119-128.
149. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin in-hibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233-242.
150. Zeng H, Yang K, Cloer C, et al. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature. 2013; 499:485-490.
151. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol. 2008;121:299-306.
152. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
153. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls pe-ripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol. 2003; 171:3348-3352.
154. Meagher C, Tang Q, Fife BT, et al. Spontaneous development of a pan-creatic exocrine disease in CD28-deficient NOD mice. J Immunol. 2008; 180:7793-7803.
155. Tang Q, Boden EK, Henriksen KJ, et al. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004;34:2996-3005.
156. Liang S, Alard P, Zhao Y, et al. Conversion of CD4+ CD25-cells into CD4 + CD25+ regulatory Tcells in vivo requires B7 costimulation, but not the thymus. J Exp Med. 2005;201:127-137.
157. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates trypto-phan catabolism in vivo. Nat Immunol. 2002;3:1097-1101.
158. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol. 2009;183:2475-2483.
159. Yan Y, Zhang GX, Gran B, et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic Tcell responses in experimental autoimmune encephalomyelitis. J Immunol. 2010;185: 5953-5961.
160. Deppong CM, Parulekar A, Boomer JS, et al. CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism. Eur J Immunol. 2010;40:1985-1994.
161. Deppong CM, Bricker TL, Rannals BD, et al. CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-β. J Immunol. 2013;191: 3082-3089.
162. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10:535-546.
163. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safetyat 5years: results from the long-term extension of the BENEFITstudy. Am J Transplant. 2013;13:2875-2883.
164. Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosup-pression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014;14:1817-1827.
165. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant. 2011;11:1359-1367.
166. Hamel KM, Cao Y, Ashaye S, et al. B cell depletion enhances Tregulatory cell activity essential in the suppression of arthritis. J Immunol. 2011;187: 4900-4906.
167. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:R83.
168. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62-74.
169. Ray A, Basu S, Williams CB, et al. A novel IL-10-independent regulatory role forB cellsin suppressing autoimmunityby maintenanceof regulatory Tcells via GITR ligand. J Immunol. 2012;188:3188-3198.
170. Kamburova EG, Koenen HJ, van den Hoogen MW, et al. Longitudinal analysis of Tand B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. PLoS One. 2014;9: e112658.
171. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95:1935-1942.
172. Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009;145:816-824.
173. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20:172-173.
174. Aydogan M, Yologlu N, Gacar G, et al. Successful rapid rituximab desen-sitization in an adolescent patient with nephrotic syndrome: Increase in number of Tregs after desensitization. J Allergy Clin Immunol. 2013; 132:478-480.
175. Sfikakis PP, Souliotis VL, Fragiadaki KG, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123:66-73.
176. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4 + Tcell immunity. Nat Rev Immunol. 2010;10:236-247.
177. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol. 2003;49(2 Suppl):S87-S97.
178. Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125:3285-3296.
179. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman pri-mates. Nat Med. 2009;15:746-749.
180. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8+ effector memory Tcells based on CD2 expression. Am J Transplant. 2011;11:22-33.
181. Lo DJ, Anderson DJ, Weaver TA, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant. 2013;13:320-328.
182. Lowe MC, Badell IR, Turner AP, et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant. 2013;13:312-319.
183. Rostaing L, Charpentier B, Glyda M, et al. Alefacept combined with ta-crolimus, mycophenolate mofetil and steroids in de novo kidney trans-plantation: a randomized controlled trial. Am J Transplant. 2013;13: 1724-1733.
184. Wojciechowski D, Vincenti F. Tofacitinib in kidney transplantation. Expert Opin Investig Drugs. 2013;22:1193-1199.
185. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302: 875-878.
186. Buckley RH. The multiple causes of human SCID. J Clin Invest. 2004; 114:1409-1411.
187. van Gurp EA, Schoordijk-Verschoor W, Klepper M, et al. The effect of the JAK inhibitor CP-690, 550 on peripheral immune parameters in stable kidney allograft patients. Transplantation. 2009;87:79-86.
188. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690, 550) in de novo kidney transplant patients: effi-cacy, renal function and safety at 1 year. Am J Transplant. 2012;12: 2446-2456.
189. Sewgobind VD, Quaedackers ME, van der Laan LJ, et al. The Jak inhib-itor CP-690, 550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. Am J Transplant. 2010;10:1785-1795.
190. Fotino C, Pileggi A. Blockade of leukocyte function antigen-1 (LFA-1) in clinical islet transplantation. Curr Diab Rep. 2011;11:337-344.
191. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7:1770-1777.
192. Posselt AM, Bellin MD, Tavakol M, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010;10:1870-1880.
193. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705-714.
194. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-189.
195. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25+ Tcell-mediated suppression by dendritic cells. Science. 2003;299:1033-1036.
196. Lal G, Yin N, Xu J, et al. Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of Foxp3 expression and Treg function. Am J Transplant. 2011;11:203-214.
197. Samanta A, Li B, Song X, et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci USA. 2008;105:14023-14027.
198. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51: 245-270.
199. Exterkate L, Slegtenhorst BR, Kelm M, et al. Frailty and Transplantation. Transplantation. 2016;100:727-733.
200. Samson M, Audia S, Janikashvili N, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:2499-2503.
201. Pesce B, Soto L, Sabugo F, et al. Effect of interleukin-6 receptor blockade on the balance between regulatory Tcells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol. 2013;171: 237-242.
202. Lei J, He F, Wu M, et al. Administration of anti-interleukin-6 monoclonal antibody prolongs cardiac allograft survival. Transpl Int. 2010;23: 1271-1281.
203. Wang H, Guan Q, Lan Z, et al. Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells. Am J Physiol Renal Physiol. 2012;302:F276-F283.
204. Fogal B, Yi T, Wang C, et al. Neutralizing IL-6 reduces human arterial al-lograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. J Immunol. 2011;187:6268-6280.
205. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2008;8:1911-1920.
206. Casiraghi F, Ruggenenti P, Noris M, et al. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. Transplantation. 1997;63:1508-1514.
207. Liang Y, Christopher K, Finn PW, et al. Graft produced interleukin-6 functions as a danger signal and promotes rejection after transplantation. Transplantation. 2007;84:771-777.
208. Waiser J, Budde K, Katalinic A, et al. Interleukin-6 expression after renal transplantation. Nephrol Dial Transplant. 1997;12:753-759.
209. Martin J, Worthington J, Harris S, et al. The influence of class II transactivator and interleukin-6 polymorphisms on the production of antibodies to donor human leucocyte antigen mismatches in renal allograft recipients. Int J Immunogenet. 2009;36:235-239.
210. Kocierz M, Siekiera U, Kolonko A, et al.-174G/C interleukin-6 gene poly-morphism and the risk of transplanted kidney failure or graft loss during a 5-year follow-up period. Tissue Antigens. 2011;77:283-290.
211. Kim I, Wu G, Chai NN, et al. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation. 2014;98:1262-1270.
212. Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immuno-globulin in difficult to desensitize patients. Transplantation. 2015;99: 2356-2363.
213. Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol. 2014; 10:14-24.
214. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 in-teracts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-122.
215. Pardoll DM. The blockade of immune checkpoints in cancer immuno-therapy. Nat Rev Cancer. 2012;12:252-264.
216. Lipson EJ, Bodell MA, Kraus ES, et al. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69-e71.
217. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother. 2015;38:211.
218. Morales RE, Shoushtari AN, Walsh MM, et al. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer. 2015;3:22.
219. Lipson EJ, Bagnasco SM, Moore J Jr, et al. Tumor regression and allo-graft rejection after administration of anti-PD-1. N Engl J Med. 2016; 374:896-898.
220. Spain L, Higgins R, Gopalakrishnan K, et al. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27:1135-1137.
221. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028.
222. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood. 2003;102:564-570.
223. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant. 2011;11:1599-1609.
224. Poirier N, Blancho G, Vanhove B. CD28-specific immunomodulating antibodies: what can be learned from experimental models? Am J Trans-plant. 2012;12:1682-1690.
225. Poirier N, Dilek N, Mary C, et al. FR104, an antagonist anti-CD28 mono-valent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant. 2015;15:88-100.
226. Mary C, Coulon F, Poirier N, et al. Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain. MAbs. 2013;5:47-55.
227. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med. 2010;2:17ra10.
228. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006;108: 253-261.
229. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of reg-ulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004;200:277-285.
230. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33-39.
231. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12:1576-1583.
232. Amrani A, Serra P, Yamanouchi J, et al. CD154-dependent priming of di-abetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells. Immunity. 2002;16:719-732.
233. Serra P, Amrani A, Yamanouchi J, et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ Tcells. Immunity. 2003;19:877-889.
234. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114.
235. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
236. Shock A, Burkly L, Wakefield I, et al. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015;17:234.
237. Tocoian A, Buchan P, Kirby H, et al. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 2015;24:1045-1056.
238. Goldwater R, Keirns J, Blahunka P, et al.A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant. 2013;13:1040-1046.
239. Ma A, Dun H, Song L, et al. Pharmacokinetics and pharmacody-namics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys. Transplantation. 2014; 97:397-404.
240. Dai H, Peng F, Lin M, et al. Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade. Transpl Immunol. 2015;32:84-91.
241. Wang H, Zhang Z, Tian W, et al. Memory Tcells mediate cardiac allograft vasculopathy and are inactivated by anti-OX40L monoclonal antibody. Cardiovasc Drugs Ther. 2014;28:115-122.
242. Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012;188: 892-901.
243. Vu MD, Xiao X, Gao W, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007;110:2501-2510.
244. Demirci G, Li XC. Novel roles of OX40 in the allograft response. Curr Opin Organ Transplant. 2008;13:26-30.
245. Di Rosa M, Malaguarnera M, Nicoletti F, et al. Vitamin D3: a helpful immuno-modulator. Immunology. 2011;134:123-139.
246. Obi Y, Hamano T, Ichimaru N, et al. Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study. J Clin Endocrinol Metab. 2014;99:527-535.
247. Kim H, Kang SW, Yoo TH, et al. The impact of pretransplant 25-hydroxy vitamin D deficiency on subsequent graft function: an observational study. BMC Nephrol. 2012;13:22.
248. Lowery EM, Bemiss B, Cascino T, et al. Low vitamin D levels are associ-ated with increased rejection and infections after lung transplantation. J Heart Lung Transplant. 2012;31:700-707.
249. Hamid K, Yusoff A, Rahman M, et al. Effective connectivity between superior temporal gyrus and Heschl's gyrus during white noise listening: linear versus non-linear models. Biomed Imaging Interv J. 2012;8:e13.